Continuous Five-Drug versus Alternating Three-Drug and Two-Drug Chemotherapy After Five-Drug or Three-Drug Induction in Extensive Small Cell Lung Cancer

R. T. Eagan Department of Oncology, Mayo Clinic Rochester, Minnesota

S. Frytak Department of Oncology, Mayo Clinic Rochester, Minnesota

E. T. Creagan Department of Oncology, Mayo Clinic Rochester, Minnesota

D. T. Coles Department of Oncology, Mayo Clinic Rochester, Minnesota; Department of Thoracic Diseases, Mayo Clinic Rochester, Minnesota

References

Alberto P, Berchtold W, Sonntag R, et al. Chemotherapy of small cell carcinoma of the lung: Comparison of cyclic alternating combination with simultaneous combination of four and seven agents. Eur J Cancer 1981; 17: 1027–1033
Web of Science ®Google Scholar
Krauss S, Lowenbraun S, Bartolucci A. Alternating non-cross-resistant drug combinations in the treatment of metastatic small cell carcinoma of the lung. Cancer Clin Trials 1981; 4: 147–151
PubMedGoogle Scholar
Lininger T R, Fleming T R, Eagan R T. Evaluation of alternating chemotherapy and sites and extent of disease in extensive small cell lung cancer. Cancer 1981; 48: 2147–2153
PubMed Web of Science ®Google Scholar
Osterlind K, Sbrenson S, Hansen H H, et al. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res 1983; 43: 6085–6089
PubMed Web of Science ®Google Scholar
Maurer L H, Pajak T F. Prognostic factors in small cell carcinoma of the lung: A cancer and leukemia group B study. Cancer Treat Rep 1981; 65: 767–774
PubMedGoogle Scholar
Cohen M H, Makirch R, Johnston-Early A, et al. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 1981; 65: 187–195
PubMedGoogle Scholar
Hirsch F R, Hansen H H. Bone marrow involvement in small cell carcinoma of the lung. Cancer 1980; 46: 206–211
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Continuous Five-Drug versus Alternating Three-Drug and Two-Drug Chemotherapy After Five-Drug or Three-Drug Induction in Extensive Small Cell Lung Cancer

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Continuous Five-Drug versus Alternating Three-Drug and Two-Drug Chemotherapy After Five-Drug or Three-Drug Induction in Extensive Small Cell Lung Cancer

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date